LYTIR

Company · XENE

Xenon Pharmaceuticals Inc.

Nasdaq's symbol directory lists XENE on Nasdaq as “Xenon Pharmaceuticals Inc. - Common Shares”.

In the 12 months to Nov 8, 2026: insiders bought on 2 occasions ($1.7M); insiders sold on 2 occasions ($1.1M); 5 filings by holders of 5% or more.

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $1.7M in total; Insider sales: $1.1M in total.Aug: Insider sales $1.1MSep: Insider purchases $1.7MDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $1.7MInsider sales below: $1.1M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. MORTIMER IAN, PRESIDENT & CEO bought on 1 day latest Sep 30, 2026 bought $1.1M
  2. GANNON STEVEN sold on 1 day latest Aug 11, 2026 sold $641K
  3. Kelly Thomas Patrick, Chief Financial Officer bought on 1 day latest Sep 30, 2026 bought $560K
  4. KENNEY CHRISTOPHER JOHN, Chief Medical Officer sold on 1 day all under a 10b5-1 plan latest Aug 28, 2026 sold $426K
Every trade (4)
  1. BUYMORTIMER IAN, PRESIDENT & CEO bought Sep 30, 2026 30,000 shares filing $1.1M
  2. BUYKelly Thomas Patrick, Chief Financial Officer bought Sep 30, 2026 15,000 shares filing $560K
  3. SELLKENNEY CHRISTOPHER JOHN, Chief Medical Officer sold Aug 28, 2026 7,068 shares 2 legs combined 10b5-1 plan (scheduled) filing $426K
  4. SELLGANNON STEVEN sold Aug 11, 2026 10,000 shares filing $641K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. T. Rowe Price Investment Management, Inc. filed Nov 6, 2026 Schedule 13G/A passive 9,996,124 shares filing 10.3%
  2. FMR LLC filed Nov 5, 2026 Schedule 13G/A passive 11,136,649 shares filing 11.5%
  3. Wellington Management Group LLP filed Aug 13, 2026 Schedule 13G/A passive filing 1.5%
  4. FMR LLC filed Aug 7, 2026 Schedule 13G/A passive 9,959,795 shares filing 10.3%
  5. FMR LLC filed Aug 6, 2026 Schedule 13G/A passive 9,599,498 shares filing 9.9%

Sources: SEC EDGAR (Forms 4 and 144) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.